Beeline Therapeutics is Biotechnology in United States that focus on T cells business. Founded in 2016. They cover business area such as developer, preclinical cell therapy, next generation, immune cell therapy, therapeutic protein, vivo, tolerance, optimal quantity, immunomodulatory cytokine, antibody, enhance Treg, antigen specificity, target receptor, researcher, localization, new cell therapy, immune-mediate human disease.
2016
( 10 years old in 2026 )
T Cells
-
1967 Wehrle Drive
Suite 1-086
Buffalo, NY 14221
United States
Private
developerpreclinical cell therapynext generationimmune cell therapytherapeutic proteinvivotoleranceoptimal quantityimmunomodulatory cytokineantibodyenhance Tregantigen specificitytarget receptorresearcherlocalizationnew cell therapyimmune-mediate human disease
* We use standard office opening hours in near Beeline Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Beeline Therapeutics is Biotechnology business from United States that founded in 2016 (10 years old in 2026), Beeline Therapeutics business is focusing on T Cells.
Beeline Therapeutics headquarter office and corporate office address is located in 1967 Wehrle Drive Suite 1-086 Buffalo, NY 14221 United States.
Beeline Therapeutics was founded in United States.
In 2026, Beeline Therapeutics is currently focus on T cells sector.
Above is snippet of Google Trends for "T cells" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Beeline Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
